Market Research Logo

Inhalable Drug Delivery Devices - Medical Devices Pipeline Assessment, 2019

Inhalable Drug Delivery Devices - Medical Devices Pipeline Assessment, 2019

Summary

GlobalData's Medical Devices sector report, “Inhalable Drug Delivery Devices - Medical Devices Pipeline Assessment, 2019 provides an overview of Inhalable Drug Delivery Devices currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Inhalable Drug Delivery Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Inhalable Drug Delivery Devices under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Inhalable Drug Delivery Devices and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry.
Reasons to buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Inhalable Drug Delivery Devices under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date.


  • Introduction
    • Inhalable Drug Delivery Devices Overview
  • Products under Development
    • Inhalable Drug Delivery Devices - Pipeline Products by Stage of under Development
      • Table Figure 1: Inhalable Drug Delivery Devices - Pipeline Products by Stage of under Development
      • Table Inhalable Drug Delivery Devices - Pipeline Products by Stage of under Development
    • Inhalable Drug Delivery Devices - Pipeline Products by Segment
      • Table Figure 2: Inhalable Drug Delivery Devices - Pipeline Products by Segment
      • Table Inhalable Drug Delivery Devices - Pipeline Products by Segment
    • Inhalable Drug Delivery Devices - Pipeline Products by Territory
      • Table Figure 3: Inhalable Drug Delivery Devices - Pipeline Products by Territory
      • Table Inhalable Drug Delivery Devices - Pipeline Products by Territory
    • Inhalable Drug Delivery Devices - Pipeline Products by Regulatory Path
      • Table Figure 4: Inhalable Drug Delivery Devices - Pipeline Products by Regulatory Path
      • Table Inhalable Drug Delivery Devices - Pipeline Products by Regulatory Path
    • Inhalable Drug Delivery Devices - Pipeline Products by Estimated Approval Date
      • Table Figure 5: Inhalable Drug Delivery Devices - Pipeline Products by Estimated Approval Date
      • Table Inhalable Drug Delivery Devices - Pipeline Products by Estimated Approval Date
    • Inhalable Drug Delivery Devices - Ongoing Clinical Trials
      • Table Figure 6: Inhalable Drug Delivery Devices - Ongoing Clinical Trials
      • Table Inhalable Drug Delivery Devices - Ongoing Clinical Trials
  • Inhalable Drug Delivery Devices - Pipeline Products under Development by Companies
    • Inhalable Drug Delivery Devices Companies - Pipeline Products by Stage of Development
      • Table Inhalable Drug Delivery Companies - Pipeline Products by Stage of Development
    • Inhalable Drug Delivery Devices - Pipeline Products by Stage of Development
      • Table Inhalable Drug Delivery Devices - Pipeline Products by Stage of Development
  • Inhalable Drug Delivery Companies and Product Overview
    • Acorda Therapeutics Inc Company Overview
      • Acorda Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Acorda Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Drug Delivery Device - Neonatal Respiratory Distress Syndrome (RDS) - Product Status
        • Table Drug Delivery Device - Neonatal Respiratory Distress Syndrome (RDS) - Product Description
    • Baxter International Inc Company Overview
      • Baxter International Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Baxter International Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table ProMaxx Microsphere - Product Status
        • Table ProMaxx Microsphere - Product Description
    • Bellerophon Therapeutics Inc Company Overview
      • Bellerophon Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Bellerophon Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table INOpulse - Product Status
        • Table INOpulse - Product Description
        • Table Bellerophon Therapeutics Inc - Ongoing Clinical Trials Overview
        • Table INOpulse - A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed, Inhaled Nitric Oxide in Subjects with Pulmonary Hypertension Associated with Pulmonary Fibrosis or Sarcoidosis on Long Term Oxygen Therapy Followed by an Optional Open-label Long Term Extension Safety Study
        • Table INOpulse - A Phase 3, Placebo Controlled, Double-blind, Randomized, Clinical Study to Determine Efficacy, Safety, and Tolerability of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo in Symptomatic Subjects with PAH (Part 1 an Part 2)
        • Table INOpulse - A Randomized, Double-blind, Placebo-controlled Dose Escalation Study to Assess the Safety and Efficacy of Pulsed iNO in Subjects with Pulmonary Hypertension Associated with Pulmonary Fibrosis on Long Term Oxygen Therapy
        • Table INOpulse - An Open-label Long-term Safety Study of Inhaled Nitric Oxide (iNO) for PAH
        • Table INOpulse - INOvation-2 Clinical Study of INOpulse Device
        • Table INOpulse - Phase IIb Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects in Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease (PH-COPD)
    • Breath Therapeutics Holding BV Company Overview
      • Breath Therapeutics Holding BV Pipeline Products & Ongoing Clinical Trials Overview
        • Table Breath Therapeutics Holding BV Pipeline Products & Ongoing Clinical Trials Overview
        • Table Lung-Targeted BOS Device - Product Status
        • Table Lung-Targeted BOS Device - Product Description
        • Table Breath Therapeutics Holding BV - Ongoing Clinical Trials Overview
        • Table Lung-Targeted BOS Device - A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine a (L-CsA) Inhalation Solution Delivered via the Pari Investigational eFlow Device plus Standard of Care Versus Standard of Care Alone in the Treatment of Bronchiolitis Obliterans Syndrome in Patients Post Double Lung Transplantation
        • Table Lung-Targeted BOS Device - A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered Via the PARI Investigational eFlow Device Plus Standard of Care Versus Standard of Care Alone in the Treatment of Bronchiolitis Obliterans Syndrome in Patients Post Single Lung Transplantation
    • Canigma A.L LTD Company Overview
      • Canigma A.L LTD Pipeline Products & Ongoing Clinical Trials Overview
        • Table Canigma A.L LTD Pipeline Products & Ongoing Clinical Trials Overview
        • Table Vaporiser Device - Product Status
        • Table Vaporiser Device - Product Description
    • Edixomed Ltd Company Overview
      • Edixomed Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Edixomed Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table NOx System - Cystic Fibrosis - Product Status
        • Table NOx System - Cystic Fibrosis - Product Description
        • Table NOx System - VAP - Product Status
        • Table NOx System - VAP - Product Description
    • iDTx Systems, Inc. Company Overview
      • iDTx Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table iDTx Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table GoPilot - Product Status
        • Table GoPilot - Product Description
    • Impel NeuroPharma Inc Company Overview
      • Impel NeuroPharma Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Impel NeuroPharma Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table POD Device - Product Status
        • Table POD Device - Product Description
        • Table Impel NeuroPharma Inc - Ongoing Clinical Trials Overview
        • Table POD Device - A Phase IIa, Randomized, Double Blind, Placebo Controlled, Single Ascending Dose, Safety and Pharmacokinetic/Pharmacodynamic Study of INP103 (POD L-dopa) Administered in the Presence of Benserazide to L-dopa Responsive Parkinson's Disease Patients
        • Table POD Device - Comparison of Devices for Intranasal Delivery of Insulin
        • Table POD Device - Open-label Study of Safety and Tolerability of Chronic Intermittent Usage for 24 or 52 Weeks of Intranasal Dihydroergotamine Mesylate (DHE) Administered Using the I123 Precision Olfactory Delivery (POD) Device [INP104, POD-DHE] in Patients with Migraine Headache: Stop 301 Trial (Safety and Tolerability of POD-DHE)
    • Kanabo Research Ltd Company Overview
      • Kanabo Research Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Kanabo Research Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Next Generation Smart VapePod MD Vaporizer - Product Status
        • Table Next Generation Smart VapePod MD Vaporizer - Product Description
        • Table VapePod - Product Status
        • Table VapePod - Product Description
    • Mallinckrodt Plc Company Overview
      • Mallinckrodt Plc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Mallinckrodt Plc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Next Generation Inomax Evolve - Product Status
        • Table Next Generation Inomax Evolve - Product Description
    • Medical Developments International Ltd Company Overview
      • Medical Developments International Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Medical Developments International Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Penthrox Inhaler - Product Status
        • Table Penthrox Inhaler - Product Description
        • Table Penthrox Inhaler - Paediatric - Product Status
        • Table Penthrox Inhaler - Paediatric - Product Description
        • Table Medical Developments International Ltd - Ongoing Clinical Trials Overview
        • Table Penthrox Inhaler - Prospective, Multicenter Trial of Methoxyflurane for Acute Trauma-related Pain in Helicopter Emergency Medical Systems and Hostile Environments: METEORA
        • Table Penthrox Inhaler - Reduction of Anterior Shoulder Dislocation Facilitated by Inhaled Low Dose Methoxyflurane - A Pilot Study
        • Table Penthrox Inhaler - Paediatric - A Randomized, Double-blind, Multicenter, Placebo Controlled Study to Evaluate the Safety and Efficacy of Methoxyflurane (PENTHROX) for the Treatment of Acute Pain in Children and Adolescents from 6 to Less Than 18 Years of Age (Presenting to an Emergency Department with Minor Trauma)
    • Medspray BV Company Overview
      • Medspray BV Pipeline Products & Ongoing Clinical Trials Overview
        • Table Medspray BV Pipeline Products & Ongoing Clinical Trials Overview
        • Table Device 0075 - Product Status
        • Table Device 0075 - Product Description
        • Table Product 0070 - Product Status
        • Table Product 0070 - Product Description
        • Table Product 0077 - Product Status
        • Table Product 0077 - Product Description
    • NeuroproteXeon Inc Company Overview
      • NeuroproteXeon Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table NeuroproteXeon Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Xenon Inhalation Device - Product Status
        • Table Xenon Inhalation Device - Product Description
        • Table NeuroproteXeon Inc - Ongoing Clinical Trials Overview
        • Table Xenon Inhalation Device - Xenon by Inhalation for Post Out of Hospital Cardiac Arrest Syndrome: XePOHCAS
    • Next Safety, Inc. Company Overview
      • Next Safety, Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Next Safety, Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Pulmonary Drug Delivery Device - Product Status
        • Table Pulmonary Drug Delivery Device - Product Description
    • Nobilis Therapeutics Inc Company Overview
      • Nobilis Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Nobilis Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Zephyrus - Product Status
        • Table Zephyrus - Product Description
        • Table Nobilis Therapeutics Inc - Ongoing Clinical Trials Overview
        • Table Zephyrus - A Double-blind, Randomized, Placebo-controlled Trial of Xenon Inhalation for Treatment of Patients with Posttraumatic Stress Disorder
    • Sandoz International GmbH Company Overview
      • Sandoz International GmbH Pipeline Products & Ongoing Clinical Trials Overview
        • Table Sandoz International GmbH Pipeline Products & Ongoing Clinical Trials Overview
        • Table FreePath Drug Delivery System - Product Status
        • Table FreePath Drug Delivery System - Product Description
    • Texas Tech University Health Sciences Center Company Overview
      • Texas Tech University Health Sciences Center Pipeline Products & Ongoing Clinical Trials Overview
        • Table Texas Tech University Health Sciences Center Pipeline Products & Ongoing Clinical Trials Overview
        • Table Inhalable Nanoparticle System - Product Status
        • Table Inhalable Nanoparticle System - Product Description
    • University of Texas Health Science Center at Houston Company Overview
      • University of Texas Health Science Center at Houston Pipeline Products & Ongoing Clinical Trials Overview
        • Table University of Texas Health Science Center at Houston Pipeline Products & Ongoing Clinical Trials Overview
        • Table Pedinap - Product Status
        • Table Pedinap - Product Description
    • Vectura Group Plc Company Overview
      • Vectura Group Plc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Vectura Group Plc Pipeline Products & Ongoing Clinical Trials Overview
        • Table VR475 Combination Device - Product Status
        • Table VR475 Combination Device - Product Description
        • Table VR647 - Product Status
        • Table VR647 - Product Description
        • Table Vectura Group Plc - Ongoing Clinical Trials Overview
        • Table VR647 - A Phase I Clinical Study of VR-647
        • Table VR647 - A Phase I Clinical Study of VR-647 in Adult Asthma Subjects
        • Table VR647 - Phase II Pharmacokinetic Study of VR-647 in Children
        • Table VR647 - Phase III Study of VR-647
    • Vero Biotech LLC Company Overview
      • Vero Biotech LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table Vero Biotech LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table GeNOsyl Acute DS - Product Status
        • Table GeNOsyl Acute DS - Product Description
        • Table GeNOSYL Chronic DS - Product Status
        • Table GeNOSYL Chronic DS - Product Description
    • VitalMIST Company Overview
      • VitalMIST Pipeline Products & Ongoing Clinical Trials Overview
        • Table VitalMIST Pipeline Products & Ongoing Clinical Trials Overview
        • Table VitalMIST - Product Status
        • Table VitalMIST - Product Description
    • Windtree Therapeutics Inc Company Overview
      • Windtree Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Windtree Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Aerosol Drug Delivery Device - Acute Lung Injury - Product Status
        • Table Aerosol Drug Delivery Device - Acute Lung Injury - Product Description
        • Table AEROSURF - Product Status
        • Table AEROSURF - Product Description
        • Table Capillary Aerosol Generator (CAG) - Product Status
        • Table Capillary Aerosol Generator (CAG) - Product Description
        • Table Windtree Therapeutics Inc - Ongoing Clinical Trials Overview
        • Table AEROSURF - A Multinational, Multicenter, Masked, Randomized, Controlled Study to Assess the Safety and Efficacy of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age with Respiratory Distress Syndrome
  • Inhalable Drug Delivery Devices - Recent Developments
    • Apr 30, 2019: Windtree Therapeutics appoints Daniel Geffken to Board of Directors
    • Apr 26, 2019: AstraZeneca: Q1 2019 results
    • Apr 25, 2019: Baxter reports first-quarter 2019 results
    • Apr 23, 2019: Catalent invests $14 million at Its Eberbach, Germany Softgel facility
    • Apr 12, 2019: Inhalation Sciences wins place on prestigious EU-funded Life Science Investment Hotlist
    • Apr 11, 2019: Catalent Celebrates opening of second Shanghai facility to optimize global and local clinical supply solutions for China
    • Apr 05, 2019: JC Pharma plans stock exchange listing to develop CannatolRx
    • Apr 02, 2019: 3M Drug Delivery Systems relocates UK R&D to new, state-of-the-art facility
    • Apr 01, 2019: Inhalation Sciences receives new Contract Research order for DissolvIt
    • Apr 01, 2019: Vectura Group names Kevin Matthews to its board of directors
    • Mar 27, 2019: Mountain rescue study launches to investigate use of Penthrox (methoxyflurane) for trauma-related pain in hostile environments
    • Mar 27, 2019: AstraZeneca leads in the development of a new International Life Science Innovation Park in China
    • Mar 26, 2019: Breath Therapeutics announces initiation of global phase 3 trials for the treatment of bronchiolitis obliterans syndrome
    • Mar 26, 2019: AstraZeneca slash almost 100 jobs in manufacturing 'hammer blow'
    • Mar 26, 2019: Vectura Group 2018 preliminary results
    • Mar 20, 2019: Breath Therapeutics announces presentations at Upcoming Scientific Conferences
    • Mar 14, 2019: Eyepoint Pharmaceuticals reports fiscal period ended december 31, 2018 financial results and highlights recent clinical and operational developments
    • Mar 14, 2019: AstraZeneca: Appointment of M s. Sarah Wang as an additional director
    • Mar 14, 2019: Bellerophon provides business update and reports fourth quarter and full-year 2018 financial results
    • Mar 14, 2019: AAP updates vaccine recommendations for 2019-2020 Flu season
    • Mar 12, 2019: Techniques for achieving high dose accuracy to be presented by Catalent Biologics experts at ISPE Aseptic Conference
    • Mar 04, 2019: Sunovion Pharmaceuticals appoints Dr. Antony Loebel as President and CEO
    • Feb 21, 2019: Inhalation Sciences Sweden year-end report 2018
    • Feb 21, 2019: Catalent Appoints Kay Schmidt to executive leadership team to lead new technical operations organization
    • Feb 19, 2019: Impel NeuroPharma names Jennifer L. Berman as vice president of marketing
    • Feb 19, 2019: Solutions for assay automation to be presented by Catalent Biologics At BEBPA US Bioassay Conference
    • Feb 15, 2019: Bristol pharmaceutical company Avara Avlon Pharma collapses putting 270 jobs at risk
    • Feb 15, 2019: Aradigm announces plans for reorganization under Chapter 11 of the U.S. Bankruptcy Code
    • Feb 14, 2019: AstraZeneca announces full-year and Q4 2018 results
    • Feb 05, 2019: Catalent reports second quarter fiscal 2019 results
    • Jan 31, 2019: Baxter reports 2018 fourth-quarter and full-year results
    • Jan 28, 2019: Bellerophon to Present Clinical Data Supporting Actigraphy as a Clinically Meaningful Endpoint to Detect Improvements in Pulmonary Fibrosis Patients
    • Jan 28, 2019: EyePoint Pharmaceuticals names David Guyer, M.D., to Board of Directors
    • Jan 22, 2019: Baptist Health Expands CORE Value Suite Roll-out Across Five Hospitals
    • Jan 09, 2019: AstraZeneca laying off 200-plus in Boulder, Longmont
    • Jan 07, 2019: Nobilis Therapeutics announces IND filing for a phase IIb clinical trial of NBTX-001 drug/device combination for treatment of posttraumatic stress disorder
    • Jan 07, 2019: Bellerophon announces top-line results from cohort 1 of the INOpulse phase 2b clinical trial for treatment of pulmonary hypertension associated with interstitial lung disease
    • Jan 07, 2019: AstraZeneca announces organisational changes
    • Jan 07, 2019: Aptamer Group and AstraZeneca sign agreement to explore feasibility of developing drug delivery vehicles
    • Jan 06, 2019: Impel Neuropharma announces positive phase 1 trial for INP105 for the treatment of acute agitation In Bipolar I Disorder and Schizophrenia
    • Jan 03, 2019: Amphastar Pharmaceuticals announces launch of Primatene MIST to nationwide retail pharmacies
    • Dec 21, 2018: NPXe Announces First Patient Enrolled in Phase III trial of XENEX Inhaled Xenon Gas Therapy
    • Dec 14, 2018: AstraZeneca: Non-executive Board changes
    • Dec 13, 2018: Update on UK GSK patent litigation
    • Dec 12, 2018: Lower-priced spacer chambers could compromise young asthma patients'' treatment
    • Dec 10, 2018: New data from the AEROSURF phase 2b clinical program shows AEROSURF appears to reduce incidence and severity of Bronchopulmonary Dysplasia in preterm infants with RDS
    • Dec 06, 2018: Baxter International names Patricia Morrison and Amy Wendell to its Board
    • Dec 06, 2018: Catalent celebrates 20 Years at Philadelphia Facility
    • Dec 04, 2018: Consort Medical delivers profit growth in the first half
    • Dec 03, 2018: Gentle treatment for premature babies with lung diseases
    • Nov 27, 2018: EyePoint Pharmaceuticals names Ron Honig, Esq., as SVP, general counsel & company secretary
    • Nov 26, 2018: Vectura announces results for late stage clinical asset VR475 in severe uncontrolled asthma
    • Nov 15, 2018: Inhalation Sciences third quarter report 2018
    • Nov 09, 2018: Vectura and Hikma to jointly develop generic versions of GSK's Ellipta
    • Nov 08, 2018: Mallinckrodt earns International Standard ISO 13485:2016 and Medical Device Single Audit Program (MDSAP) certifications for INOmax DSIR Plus Nitric Oxide Delivery Systems
    • Nov 08, 2018: Statement from FDA Commissioner Scott Gottlieb, M.D., and Janet Woodcock, M.D., director of the Center for Drug Evaluation and Research, on approval of OTC Primatene Mist to treat mild asthma
    • Nov 08, 2018: AstraZeneca: Year-to-date and Q3 2018 results
    • Nov 07, 2018: Amphastar Pharmaceuticals announces reintroduction of Primatene MIST
    • Nov 07, 2018: Bellerophon provides business update and reports third quarter 2018 financial results
    • Nov 07, 2018: Impel NeuroPharma names Ellen A. Lubman as chief business officer
    • Nov 06, 2018: UDG Healthcare: Director declaration 2018
    • Nov 06, 2018: Consort Medical announces its board change
    • Nov 06, 2018: EyePoint Pharmaceuticals reports fiscal first quarter 2019 financial results and highlights recent clinical and operational developments
    • Oct 31, 2018: Baxter reports third-quarter 2018 results and updates financial outlook for full-year 2018
    • Oct 31, 2018: Vectura Group: Directorate change
    • Oct 30, 2018: EyePoint Pharmaceuticals appoints John Landis, Ph.D., M.S., to Board of Directors
    • Oct 23, 2018: Penthrox approved in Hong Kong
    • Oct 22, 2018: Vectura group has announced the board change
    • Oct 22, 2018: Softhale announces New Board Member
    • Oct 17, 2018: Camallergy Appoints Baxter Phillips III as Chief Executive Officer
    • Oct 11, 2018: Penthrox is approved in Saudi Arabia
    • Oct 09, 2018: Bellerophon provides update on INOpulse phase 2b clinical program for treatment of pulmonary hypertension associated with interstitial lung disease
    • Oct 09, 2018: Astrazeneca sues block Zydus Cadila bid generic nexium
    • Oct 02, 2018: PARI Pharma's eFlow Technology device, LAMIRA, approved as the only nebulizer system to deliver Insmed's ARIKAYCE
    • Sep 19, 2018: Inhalation Sciences receives 2.4 MSEK order from global corporation based in Europe
    • Sep 12, 2018: Consort to develop delivery device for opioid overdose drug
    • Sep 12, 2018: EyePoint Pharmaceuticals reports fiscal 2018 fourth quarter & full year financial results and highlights recent progress
    • Sep 11, 2018: Vectura Group: Interim Results
    • Sep 10, 2018: EyePoint Pharmaceuticals names Goran Ando as Next Chairman of Board of Directors
    • Sep 06, 2018: AstraZeneca: Directorate change
    • Aug 30, 2018: Penthrox Paediatric trial: Safety update
    • Aug 30, 2018: Catalent experts to discuss ways to accelerate biologics development and manufacturing at Bioprocess International Conference
    • Aug 29, 2018: Medical Developments International announce Penthrox Inhaler USA update
    • Aug 29, 2018: Impel Neuropharma announces first subject dosed in phase 1 trial evaluating INP105 for the treatment of acute agitation in bipolar I disorder and schizophrenia
    • Aug 28, 2018: Catalent announces fourth quarter fiscal 2018 financial results
    • Aug 24, 2018: Cadila Healthcare's Biologics manufacturing facility successfully completes USFDA inspection
    • Aug 23, 2018: Mallinckrodt and NPXE announce FDA fast track designation for phase 3 trial of inhaled xenon gas therapy
    • Aug 22, 2018: Impel NeuroPharma announces first patient dosed in phase 3 trial evaluating INP104 for the treatment of Acute Migraine Headache
    • Aug 22, 2018: Inhalation Sciences publishes interim report for the second quarter of 2018
    • Aug 21, 2018: Vectura Group announces positive findings from its VR647 Phase II pharmacokinetic and mouthpiece methodology studies
    • Aug 16, 2018: Nu-Med optimistic about nitric oxide prospects after patent ruling
    • Aug 15, 2018: Eyepoint Pharmaceuticals appoints John Weet, Ph.D., as SVP, regulatory affairs & quality
    • Aug 14, 2018: Aradigm announces second quarter 2018 financial results
    • Aug 07, 2018: Bellerophon announces results of interim analysis of phase 3 INOvation-1 study evaluating INOpulse for treatment of pulmonary arterial hypertension
    • Aug 06, 2018: Inhalation Sciences wins Contract Research order worth 0.6 MSEK from leading European inhalation company
    • Aug 06, 2018: Anvisa suspends sale and use of lots of nasal decongestant
    • Aug 01, 2018: AstraZeneca faces US DOJ probe for alleged funding of Iraqi terrorists
    • Aug 01, 2018: Bellerophon provides business update and reports second quarter 2018 financial results
    • Jul 31, 2018: Nu-Med Plus Approaches Landmark Certification to Speed New Nitric Oxide Medical Device Approval
    • Jul 26, 2018: Baxter Reports Second-Quarter 2018 Results and Increases Earnings Outlook for Full- Year 2018
    • Jul 25, 2018: Medical Developments International announce USA Update
    • Jul 23, 2018: Windtree announces completion of new design development for its Aerosol Delivery System (ADS) including successful performance testing
    • Jul 16, 2018: Penthrox approved in Italy, The Czech Republic and Spain
    • Jul 16, 2018: Impel NeuroPharma Strengthens Leadership Team With Appointment Of Lynn C. Gold As Senior Vice President Of Regulatory Affairs
    • Jul 16, 2018: Vectura Appoints Paul Fry as Chief Financial Officer and Executive Director
    • Jul 12, 2018: Catalent Appoints Marlene Leuenberger As General Manager Of New Drug Development Center Of Excellence
    • Jul 06, 2018: Aradigm Names Dr. Theresa Matkovits As Board Director
    • Jun 28, 2018: Baxter Releases 2017 Corporate Responsibility Report and Reinforces Its Commitment to Enriching Communities Around the World
    • Jun 26, 2018: EyePoint Pharmaceuticals Names Goran Ando As Board Director
    • Jun 26, 2018: Catalent Biologics Names Dr. Graham Brearley As General Manager of its Madison, Wisconsin Facility
    • Jun 25, 2018: Penthrox approved in Portugal and Switzerland
    • Jun 21, 2018: MedPharm Licenses Its MedSpray Technology to Virpax
    • Jun 14, 2018: Consort Medical delivered another year of good growth in revenue and profit
    • Jun 13, 2018: Catalent Pharma Solutions Names Paul Hegwood As New President Of Clinical Supply Services
    • Jun 01, 2018: Vectura Group Appoints Anne Whitaker As Non-Executive Director
    • May 31, 2018: Windtree Therapeutics'' Aerosolized KL4 Surfactant Preclinical Data in Influenza Presented at the 2018 American Thoracic Society Meeting
    • May 22, 2018: Windtree Receives $0.7 Million SBIR Grant in Continuing Support of the AEROSURF Phase 2b Clinical Trial Completion
    • May 21, 2018: Baxter Highlights Business Strategies and Innovation at 2018 Investor Conference
    • May 17, 2018: Catalent Completes $5.5 Million Phased Clinical Storage Expansion At Kansas City Campus
    • May 16, 2018: Bellerophon to Present Positive Results from Phase 2 Study of INOpulse for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease at the American Thoracic Society 114th International Conference
    • May 16, 2018: EyePoint Pharmaceuticals Announces Appointment of Leonard Blum as Executive Vice President and General Manager, U.S.
    • May 15, 2018: Aradigm Reports First Quarter 2018 Financial Results
    • May 10, 2018: Bellerophon Provides Business Update and Reports First Quarter 2018 Financial Results
    • May 09, 2018: European Distribution Partnership between NeuroproteXeon and Linde
    • May 08, 2018: Bellerophon Reaches Agreement with FDA on Study Design of Phase 2b Trial of INOpulse for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease
    • May 08, 2018: Inhalation Sciences' new CEO Lena Heffler: science, sales, win-win
    • May 08, 2018: EyePoint Pharmaceuticals Reports Fiscal Third Quarter 2018 Results
  • Appendix
    • Methodology
      • Table Glossary
    • About GlobalData
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook